APGE
USDApogee Therapeutics Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$55.000
Максимум
$55.930
Минимум
$52.340
Объем
1.04M
Фундаментальные показатели компании
Рыночная капитализация
3.7B
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
0.66M
Биржа
NGM
Валюта
USD
52-недельный диапазон
Связанные новости
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026,
Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109
Craig-Hallum analyst Adam Vogel initiates coverage on Apogee Therapeutics with a Buy rating and announces Price Target of $109.
RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70
RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics with a Outperform and raises the price target from $60 to $70.
Apogee Therapeutics to Participate in Upcoming Conferences
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105
Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics with a Outperform rating and announces Price Target of $105.
Связанные акции
DLY
DoubleLine Yield Opportunities Fund Common Shares of Beneficial Interest
LVTX
LAVA Therapeutics N.V. Ordinary Shares
EOSEW
Eos Energy Enterprises Inc. Warrant
BLEU
bleuacacia ltd Ordinary Shares
BODI
The Beachbody Company Inc.
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.